RecruitingNCT07136714
Semaglutide or placebo with usual care for depression and obesity
About this title
Read the official source — NCT07136714This study assesses depression symptoms.
Medication studyAges 18–65Denmark
Understand this study
What is this study about?
This study assesses depression symptoms.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
The protocol includes: Completing questionnaires.
- Listed locations
- HillerødSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 11, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 116
- Sponsor
- Nordsjaellands Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Denmark
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07136714
- Official title
Show the full official title
Is the GLP-1 Receptor Agonist Semaglutide Able to Alleviate Mood in Patients With Major Depressive Disorder and Overweight or Obesity
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Hillerød
Interested in joining this study?
Questions about this study
What is this study about?
This study assesses depression symptoms.
What will I need to do?
You will complete questionnaires.
Who is behind this study?
The study sponsor is Nordsjaellands Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide Injectable Product and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Flumazenil during ECT and thinking or memory in depression or bipolarity
Lithium versus cariprazine for depression in bipolarity